ADVANZ PHARMA Corp. Announces Fourth Quarter and Fiscal 2018 Results

Company acquires international rights to SalagenĀ® tablets (pilocarpine hydrochloride) (excluding Japan rights) and PanretinĀ® (alitretinoin) gel 0.1% from Eisai Inc. for $30 million in cash plus approximately $3.3 million for purchased inventory and related prepayments. ADVANZ PHARMA will pay for the acquisition with cash on hand.